Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Annapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerCarcinoma in situBCG-unresponsive NMIBCBladder-sparing therapyOncological outcomesTumor stageBladder cancer mortalityCancer mortalityAssociated with worse oncologic outcomesPresence of carcinoma in situCarcinoma in situ groupImpact of tumor stageTA groupKaplan-Meier methodPapillary diseaseT1 diseaseRadical cystectomyNo significant differenceClinical stageBladder cancerSurvival differencesRetrospective natureCis groupDisease progressionMetastasis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply